Primary prevention of beta-cell autoimmunity and type 1 diabetes – The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) perspectives
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Type 1 diabetes can be identified by the presence of beta-cell autoantibodies that often arise in the first few years of life. The purpose of this perspective is to present the case for primary prevention of beta-cell autoimmunity and to provide a study design for its implementation in Europe. METHODS: We examined and summarized recruitment strategies, enrollment rates, and outcomes in published TRIGR, FINDIA and BABYDIET primary prevention trials, and the TEDDY intensive observational study. A proposal for a recruitment and implementation strategy to perform a phase II/III primary prevention randomized controlled trial in infants with genetic risk for developing beta-cell autoimmunity is outlined. RESULTS: Infants with a family history of type 1 diabetes (TRIGR, BABYDIET, TEDDY) and infants younger than age 3 months from the general population (FINDIA, TEDDY) were enrolled into these studies. All studies used HLA genotyping as part of their eligibility criteria. Predicted beta-cell autoimmunity risk in the eligible infants ranged from 3% (FINDIA, TEDDY general population) up to 12% (TRIGR, BABYDIET). Amongst eligible infants, participation was between 38% (TEDDY general population) and 97% (FINDIA). Outcomes, defined as multiple beta-cell autoantibodies, were consistent with predicted risks. We subsequently modeled recruitment into a randomized controlled trial (RCT) that could assess the efficacy of oral insulin treatment as adapted from the Pre-POINT pilot trial. The RCT would recruit infants with and without a first-degree family history of type 1 diabetes and be based on general population genetic risk testing. HLA genotyping and, for the general population, genotyping at additional type 1 diabetes susceptibility SNPs would be used to identify children with around 10% risk of beta-cell autoimmunity. The proposed RCT would have 80% power to detect a 50% reduction in multiple beta-cell autoantibodies by age 4 years at a two-tailed alpha of 0.05, and would randomize around 1160 infants to oral insulin or placebo arms in order to fulfill this. It is estimated that recruitment would require testing of between 400,000 and 500,000 newborns or infants. CONCLUSION: It is timely and feasible to establish a platform for primary prevention trials for type 1 diabetes in Europe. This multi-site European infrastructure would perform RCTs, supply data coordination and biorepository, provide cohorts for mechanistic and observational studies, and increase awareness for autoimmune diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Randomized trial of peanut consumption in infants at risk for peanut allergy
Du Toit, G., Roberts, G., Sayre, P. H., Bahnson, H. T., Radulovic, S., Santos, A. F., Brough, H. A., Phippard, D., Basting, M., Feeney, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414850 · Cited by 2,237
Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children
Ziegler, A. G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., Winkler, C., Ilonen, J., Veijola, R., Knip, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.6285 · Cited by 1,312
Self-citationInsulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus
Vafiadis, P., Bennett, S. T., Todd, J. A., Nadeau, J., Grabs, R., Goodyer, C. G., Wickramasinghe, S., Colle, E., & Polychronakos, C. (1997) · Nature Genetics · doi:10.1038/ng0397-289 · Cited by 809 · cited 1×
“Allelic variation in the insulin gene is associated with type 1 diabetes [21] and islet autoimmunity [22] via a mechanism of thymic T cell deletion [23].”
BackgroundSelf-citationEffects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
The Diabetes Prevention Trial-Type 1 Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1068 · Cited by 668 · cited 1×
“%) met the HLA eligibility criteria; of newborns with a first-degree relative, 1456 (22.6”
BackgroundInfluentialTiming of initial cereal exposure in infancy and risk of islet autoimmunity
Norris, J. M. (2003) · JAMA · doi:10.1001/jama.290.13.1713 · Cited by 515 · cited 1×
“Evidence came from two natural history studies, BABYDIAB and the Diabetes and Autoimmunity Study in the Young (DAISY), which demonstrated that early gluten exposure is associated with increased risk of beta-cell autoimmunity in childhood [12,13].”
Prediction and Pathogenesis in Type 1 Diabetes
Ziegler, A.-G., & Nepom, G. T. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.018 · Cited by 346 · cited 1×
“com antigens and is mediated by a lack of immunological self-tolerance [1,2].”
BackgroundSelf-citationAge-related islet autoantibody incidence in offspring of patients with type 1 diabetes
the BABYDIAB-BABYDIET Study Group, Ziegler, A.-G., & Bonifacio, E. (2012) · Diabetologia · doi:10.1007/s00125-012-2472-x · Cited by 264
Self-citationParikka, V., Näntö-Salonen, K., Saarinen, M., Simell, T., Ilonen, J., Hyöty, H., Veijola, R., Knip, M., & Simell, O. (2012) · Diabetologia · doi:10.1007/s00125-012-2523-3 · Cited by 235
Vaarala, O., Ilonen, J., Ruohtula, T., Pesola, J., Virtanen, S. M., Härkönen, T., Koski, M., Kallioinen, H., Tossavainen, O., Poussa, T., et al. (2012) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpediatrics.2011.1559 · Cited by 127 · cited 1×
“…Universität München, Ingolstädter entrum München, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany 3Diabetes , 30173 Hannover, Germany 4Department of Paediatrics, University of Cambridge, Carus, Technische Universität Dresden, Dresden, Germany 6University Hospital for g, Germany 7The…”
Background
Cited by
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31320-5 · Cited by 1,561
Sharp, S. A., Rich, S. S., Wood, A. R., Jones, S. E., Beaumont, R. N., Harrison, J. W., Schneider, D. A., Locke, J. M., Tyrrell, J., Weedon, M. N., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1785 · Cited by 366
Haller, M. J., Bell, K. J., Besser, R. E. J., Casteels, K., Couper, J. J., Craig, M. E., Elding Larsson, H., Jacobsen, L., Lange, K., Oron, T., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543035 · Cited by 151
“Nevertheless, more than 90% of children diagnosed with T1D do not have a family history of this condition [8, 9].”
Self-citationBonifacio, E., Beyerlein, A., Hippich, M., Winkler, C., Vehik, K., Weedon, M. N., Laimighofer, M., Hattersley, A. T., Krumsiek, J., Frohnert, B. I., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002548 · Cited by 148
Self-citationA combined risk score enhances prediction of type 1 diabetes among susceptible children
Ferrat, L. A., Vehik, K., Sharp, S. A., Lernmark, Å., Rewers, M. J., She, J.-X., Ziegler, A.-G., Toppari, J., Akolkar, B., Krischer, J. P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0930-4 · Cited by 148
Self-citation
Metadata
- Authors
- Ziegler, A. G., Danne, T., Dunger, D. B., Berner, R., Puff, R., Kiess, W., Agiostratidou, G., Todd, J. A., & Bonifacio, E.
- Venue
- Molecular Metabolism
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 5
- Issue
- 4
- Pages
- 255-262
- ISSN
- 2212-8778 (ISSN-L)
- OpenAlex
- W2277933781
- Cited by
- 67
- References
- 9
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.